Related Experiment Video
Updated: Jun 12, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
State of the science: beta-blockers and reduction of perioperative cardiac events
1Texas Tech University Health Sciences Center, Anita Thigpen Perry School of Nursing, 3601 4th Street, Stop 6264, Lubbock, TX 79430-6264, USA. Seth.Stephens@ttuhsc.edu
Abstract:
This article evaluates the current literature concerning the use of perioperative beta-blockade to reduce cardiac events in hopes that it may provide direction to clinicians or demonstrate gaps in medical knowledge, thus revealing areas suitable for future study. The current standard of practice for the use of perioperative beta-blockade in preoperative patients is outlined in the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines. Findings differ as to the risk and benefit of using beta-blockers perioperatively to reduce cardiac events. Further research is needed to support the ACC/AHA recommendations. It is essential that the decision to use beta-blockade be made on a case-by-case basis with adequate risk stratification as part of the criteria.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers